Inhibitors of angiogenesis in a clinical perspective.
Inhibition of angiogenesis or preventing the outgrowth of new blood vessels towards a tumor is one of the most promising areas of anticancer drug development. Several angiogenesis inhibitors are now on the verge of being tested in clinical trials. This review discusses possible applications of inhibitors of angiogenesis and whether the current methodologies for testing novel anticancer drugs are appropriate to evaluate the efficacy of inhibitors of angiogenesis.
Voest
E E
EE
Department of Internal Medicine and Medical Oncology, University Hospital Utrecht, The Netherlands.
D043168:Angiostatins; D003510:Cyclohexanes; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors; D008222:Lymphokines / Q000037:antagonists & inhibitors; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000517:prevention & control; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D010446:Peptide Fragments / Q000037:antagonists & inhibitors; D010958:Plasminogen / Q000037:antagonists & inhibitors; D010978:Platelet Factor 4 / Q000037:antagonists & inhibitors; D012717:Sesquiterpenes / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D003510:Cyclohexanes; D016228:Endothelial Growth Factors; D016023:Integrins; D008222:Lymphokines; D010446:Peptide Fragments; D012717:Sesquiterpenes; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D010978:Platelet Factor 4; D043168:Angiostatins; D010958:Plasminogen; D008666:Metalloendopeptidases; D000077609:O-(Chloroacetylcarbamoyl)fumagillol